戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 quinone, a late biosynthetic intermediate of vitamin K1.
2 re fed a diet supplemented with warfarin and vitamin K1.
3  of the oxidized primary donor and a reduced vitamin K1.
4 ticoagulation clinic examined the effects of vitamin K1 100 mug daily on INR variability and found no
5 in-like CXXC center involved in reduction of vitamin K1 2,3-epoxide (Vit.K>O).
6          Changes in plasma phylloquinone and vitamin K1-2,3-epoxide were no different in the two grou
7 1.3+/-9.0 nmol x h/L for the lipid group for vitamin K1-2,3-epoxide).
8  vitamin K deficiency and minidose warfarin, vitamin K1-2,3-epoxide, PIVKA-II, and percentage underca
9 serial measurements of plasma phylloquinone, vitamin K1-2,3-epoxide.
10 in E (150 ug), pantothenic acid (50 ug), and vitamin K1 (25 ug).
11 owever, when diabetic rats were treated with vitamin K1 (5 mg/kg, sc, twice a week) it resulted in lo
12                                     Finally, vitamin K1 absorption was compared between wild-type mic
13        A significant interaction between low vitamin K1 and antihypertension medication use was detec
14 rew on brucella blood agar supplemented with vitamin K1 and hemin and on brucella laked blood agar su
15  brucella laked blood agar supplemented with vitamin K1 and hemin.
16 idant, we report here the novel finding that vitamin K1 and K2 (menaquinone-4) potently inhibit gluta
17 els of affinity, first for NADPH, second for vitamin K1 and third for the substrate DL-glyceraldehyde
18 post hoc analysis of the ViKCoVaC (effect of Vitamin-K1 and Colchicine on Vascular Calcification acti
19                               Phylloquinone (vitamin K1) and menaquinones (vitamin K2 family) are ess
20 cella agar supplemented with 5% sheep blood, vitamin K1, and hemin.
21 hydroxy-2'-deoxyguanosine (8OHdG) and plasma Vitamin K1 as a marker of protocol adherence.
22     This study investigated the potential of vitamin K1 as a novel lens aldose reductase inhibitor in
23    Overall, our study shows the potential of vitamin K1 as an ALR2 inhibitor which primarily blocks e
24 ction monitoring mode with deuterium-labeled vitamin K1 as an internal standard.
25 e absorption and transport of phylloquinone (vitamin K1) by plasma lipoproteins.
26 ignal can be directly attributed to A-1, and vitamin K1 can be assigned as this PSI acceptor.
27  CAC progression for subjects with low serum vitamin K1 compared with subjects without extreme CAC pr
28                                      A serum vitamin K1 concentration was considered low at <1.0 nmol
29 ding site of ALR2, which probably shows that vitamin K1 could possibly bind both these sites in the e
30 ti-inflammatory factors of the diet, such as vitamin K1, could play a protective role.
31 iabetes mellitus, supplementation with 10 mg vitamin K1/d may prevent the development of newly calcif
32 ntration) and bioaccessibility of vitamin C, vitamin K1, glucosinolates, S-alk(en)yl-l-cysteine sulfo
33 nge was +5 +/- 20 Agatston units (AU) in the vitamin K1 group (n = 40) and +44 +/- 13 AU in the place
34 nd the direct carboxylase inhibitor 2-chloro-vitamin K1 have no effect on the protective function of
35 ive, and specific analytical method to study vitamin K1 in fruits and vegetables.
36 c properties of provitamin A, vitamin E, and vitamin K1 in the gas phase for the first time.
37   To examine the association between dietary vitamin K1 intake and the risk of incident cataracts in
38 rticipants in the highest tertile of dietary vitamin K1 intake had a lower risk of cataracts than tho
39                                      Dietary vitamin K1 intake was evaluated using a validated food f
40                           Low phylloquinone (vitamin K1) intake is a potential risk factor for bone f
41 mice compared with wild-type mice, but their vitamin K1 intestinal content remained unchanged.
42 he ability to convert dietary phylloquinone (vitamin K1) into menaquinone-4 (vitamin K2) and store th
43 ectrofluorimetric analyses clearly show that vitamin K1 is a potent inhibitor of ALR2 and this inhibi
44                   These results suggest that vitamin K1 is a potent inhibitor of lens aldose reductas
45 of warfarin and administering 2.5 mg of oral vitamin K1 is a reliable, safe, and inexpensive way to r
46 e of our primary analysis suggests low serum vitamin K1 is associated with greater CAC progression, t
47  liver to preserve coagulation function when vitamin K1 is limiting.
48             In 68 of 71 patients (96%), oral vitamin K1 lowered the INR from between 5.0 and 10.0 to
49 es of warfarin, administering 2.5 mg of oral vitamin K1, measuring the INR after 24 to 48 hours, and
50            Dietary intakes of phylloquinone (vitamin K1), menaquinones (vitamin K2), and dihydrophyll
51           Treatment with large doses of oral vitamin K1, often over months to years, to maintain a ne
52 d agar (the last three media did not contain vitamin K1 or hemin).
53  At the same time docking also suggests that vitamin K1 overlaps at the NADPH binding site of ALR2, w
54 as lacked nationally representative data for vitamin K1 (phylloquinone) in horticultural commodities.
55                                              Vitamin K1 (phylloquinone) intestinal absorption is thou
56 tablish content of eight vitamin K vitamers, vitamin K1 (phylloquinone; PK) and vitamin K2 (menaquino
57                They add to the evidence that vitamin K1/phylloquinone concentrations vary markedly be
58                                  We measured vitamin K1/phylloquinone in duplicate in 95 composite sa
59          The greatest mean concentrations of vitamin K1/phylloquinone were found in kale (565 mug/100
60           Despite earlier acceptance of oral vitamin K1 (phytonadione) for the treatment of excessive
61 anar with the ring) conformations of UQ- and vitamin K1- radicals is estimated to be sufficiently lar
62  needed to determine whether improving serum vitamin K1 reduces CAC progression, especially in hypert
63 seline 18F-NaF PET imaging, followed by oral vitamin K1 supplementation (10 mg/d) or placebo for 3 mo
64 pective study and two prospective studies of vitamin K1 supplementation (with doses ranging from 100
65 ted whether individuals randomly assigned to vitamin K1 supplementation had reduced development of ne
66                                              Vitamin K1 supplementation independently decreased the o
67                We aimed to determine whether vitamin K1 supplementation inhibits arterial calcificati
68 by using post hoc per-protocol analyses of a vitamin K1 supplementation trial.
69 as to determine the effect of phylloquinone (vitamin K1) supplementation on CAC progression in older
70  nature of binding and inhibition of ALR2 by vitamin K1 that could open up possibilities of its thera
71  of the preferential distribution of dietary vitamin K1 to the liver to preserve coagulation function
72 s with SR-BI and CD36 significantly enhanced vitamin K1 uptake, which was subsequently decreased by t
73 id transport via SR-BI) blocked up to 85% of vitamin K1 uptake.
74 roteins is dependent on formation of reduced vitamin K1 (Vit.K1H2) in the endoplasmic reticulum (ER),
75  approach for the simultaneous estimation of vitamin K1 (VK1) and heparin via cascaded channel multia
76                       High intake of dietary vitamin K1 was associated with a reduced risk of catarac
77                          Apical transport of vitamin K1 was examined using Caco-2 TC-7 cell monolayer
78                                    Low serum vitamin K1 was significantly associated with CAC progres
79                         Serum phylloquinone (vitamin K1) was measured in 296 participants with extrem
80 Hypertension medication users with low serum vitamin K1 were more likely to have extreme CAC progress
81 n K status is low, and plasma phylloquinone (vitamin K1), which decreases when vitamin K status is lo